| International Session（Symposium）2(JSH・JSGE・JSGCS) |
| Thu. October 31st 14:30 - 17:00 Room 11: Portopia Hotel South Wing Topaz |
Clinical characteristics of chronic hepatitis B patients with hepatocellular carcinoma receiving long-term nucleos(t)ide analogue administration
|
|||
| Kazuhiro Murai1, Hayato Hikita1, Tetsuo Takehara1 | |||
| 1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine | |||
|
|||
|
|||
| Background and aim: Nucleos(t)ide analogues (NUCs) are current treatments for chronic hepatitis B (CHB), reducing hepatocellular carcinoma (HCC) occurrence, but not completely. We aimed to identify HCC occurrence rates and associated risk factors in CHB patients on long-term NUCs treatment. Methods: We analyzed CHB patients who received initial treatment with NUCs from July 2000 to March 2019. Patients who developed HCC before and within 1 year of starting NUC treatment were excluded. Results: Total 703 CHB patients including 143 cirrhotic patients received initial treatment with NUCs. During median follow-up 106.2 months, 110 patients developed HCC. By using cox proportional hazard model, the presence of cirrhosis, higher age, and higher γ-GTP at NUCs initiation are independent risk factors for HCC occurrence. The cumulative HCC occurrence rate from 1 year after NUC treatment was significantly higher in cirrhotic patients than in the non-cirrhotic patients (5 years: 37.2% vs 4.4%, 7 years: 42.6% vs 7.7%, p<0.0001). That from 5 years after NUC treatment did not decrease non-cirrhotic patients, while it decreased but remained higher in cirrhotic patients (5 years: 22.1% vs 6.7%, 7 years: 29.2% vs 9.3%, p<0.0001). Conclusion: Cirrhosis, higher age, and higher γ-GTP increased HCC risk. After NUC initiation, the HCC occurrence undiminished in non-cirrhotic patients over the long term, while it decreased but remained higher in cirrhotic patients. |
|||
|
Index Term 1: HBV Index Term 2: NUC |
|||
| Page Top | |||